Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 31, 2019

Study Completion Date

December 31, 2019

Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)Epistaxis
Interventions
DRUG

Floseal

Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.

OTHER

Packing

If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).

Trial Locations (1)

M5B 1W8

St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

The Ottawa Hospital

OTHER

lead

Unity Health Toronto

OTHER

NCT02638012 - Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT) | Biotech Hunter | Biotech Hunter